Table 2.

Patient disposition

	R/I to imatinib or dasatinib (n = 33)	Newly diagnosed (n = 25)
Treatment ongoing	23 (69.7)	15 (60.0)
End of treatment	10 (30.3)	10 (40.0)
Primary reason for end of treatment
Adverse events	5 (15.2)	6 (24.0)
Lack of efficacy*	1 (3.0)	3 (12.0)
Patient withdrew consent	0	1 (4.0)
Bone marrow transplant	1 (3.0)	0
Disease progression	1 (3.0)	0
Protocol deviation†	2 (6.1)	0

Data are presented as number (%).

^*A patient in the R/I cohort who was not in MMR at cycle 15 discontinued after 14.8 months of study drug exposure. Three patients in the newly diagnosed cohort discontinued because of lack of efficacy: 1 with BCR-ABL1^IS >10% discontinued after 6.3 months of study drug exposure, 1 with disease progression according to the investigator (but not meeting protocol criteria for progression) discontinued after 19.6 months of study drug exposure, and 1 with loss of MMR discontinued after 13.5 months of study drug exposure.

^†Protocol deviations were 2 cases of noncompliance.